Modafinil treatment for fatigue in HIV/AIDS: A randomized placebo-controlled study

Journal of Clinical Psychiatry

Volumn 71, Issue 6, 2010, Pages 707-715

  Rabkin, Judith G ^a,b   McElhiney, Martin C ^a,b   Rabkin, Richard ^a,b   McGrath, Patrick J ^a,b  

^a Columbia University ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MODAFINIL; PLACEBO; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANXIETY; ARTICLE; ASSAY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENERGY; FATIGUE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; NAUSEA; NERVOUSNESS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; ANTI-RETROVIRAL AGENTS; BENZHYDRYL COMPOUNDS; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM STIMULANTS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FOLLOW-UP STUDIES; HIV; HIV INFECTIONS; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PLACEBOS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77953763349     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05171bro     Document Type: Article

References (60)

1. Breitbart W, McDonald MV, Rosenfeld B, et al. Fatigue in ambulatory AIDS patients. J Pain Symptom Manage. 1998;15(3):159-167.
2. Leserman J, Barroso J, Pence BW, et al. Trauma, stressful life events and depression predict HIV-related fatigue. AIDS Care. 2008;20(10):1258-1265.
3. Henderson M, Safa F, Easterbrook P, et al. Fatigue among HIV-infected patients in the era of highly active antiretroviral therapy. HIV Med. 2005;6(5):347-352.
4. Justice AC, Rabeneck L, Hays RD, et al; Outcomes Committee of the AIDS Clinical Trials Group. Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms. J Acquir Immune Defic Syndr. 1999;21(2):126-133.
5. Barroso J, Lynn MR. Psychometric properties of the HIV-related Fatigue Scale. J Assoc Nurses AIDS Care. 2002a;13(1):66-75.
6. Ferrando S, Evans S, Goggin K, et al. Fatigue in HIV illness: relationship to depression, physical limitations, and disability. Psychosom Med. 1998;60(6):759-764.
7. Jenkin P, Koch T, Kralik D. The experience of fatigue for adults living with HIV. J Clin Nurs. 2006;15(9):1123-1131.
8. van Gorp WG, Baerwald JP, Ferrando SJ, et al. The relationship between employment and neuropsychological impairment in HIV infection. J Int Neuropsychol Soc. 1999;5(6):534-539.
9. Duran S, Spire B, Raffi F, et al; APROCO Cohort Study Group. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials. 2001;2(1):38-45. (Pubitemid 32181748)
10. Molassiotis A, Callaghan P, Twinn SF, et al. Correlates of quality of life in symptomatic HIV patients living in Hong Kong. AIDS Care. 2001;13(3):319-334. (Pubitemid 32578940)
11. Corless IB, Voss JG, Nicholas PK, et al. Fatigue in HIV/AIDS patients with comorbidities. Appl Nurs Res. 2008;21(3):116-122.
12. Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19(1):29-33.
13. Nieschlag E, Behre H. Pharmacology and Clinical Uses of Testosterone. Testosterone: Action, Deficiency, Substitution. New York, NY: Springer-Verlag; 1990:92-108.
14. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37(2):443-451. (Pubitemid 36152544)
15. Sullivan PS, Dworkin MS; Adult and Adolescent Spectrum of HIV Disease Investigators. Prevalence and correlates of fatigue among persons with HIV infection. J Pain Symptom Manage. 2003;25(4):329-333.
16. Pence BW, Barroso J, Harmon JL, et al. Chronicity and remission of fatigue in patients with established HIV infection. AIDS Patient Care STDS. 2009;23(4):239-244.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Editon. Washington, DC: American Psychiatric Association; 1994.
18. Perkins DO, Leserman J, Stern RA, et al. Somatic symptoms and HIV infection: relationship to depressive symptoms and indicators of HIV disease. Am J Psychiatry. 1995;152(12):1776-1781.
19. Barroso J, Carlson JR, Meynell J. Physiological and psychological markers associated with HIV-related fatigue. Clin Nurs Res. 2003;12(1):49-68. (Pubitemid 38543430)
20. Millikin CP, Rourke SB, Halman MH, et al. Fatigue in HIV/AIDS is associated with depression and subjective neurocognitive complaints but not neuropsychological functioning. J Clin Exp Neuropsychol. 2003;25(2):201-215.
21. Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry. 2000;57(2):141-147, discussion 155-156. (Pubitemid 30075264)
22. Breitbart W, Rosenfeld B, Kaim M, et al. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with HIV disease. Arch Intern Med. 2001;161(3):411-420.
23. Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2000;61(6):436-440. (Pubitemid 30452211)
24. Rabkin JG, Wagner GJ, McElhiney MC, et al. Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. J Clin Psychopharmacol. 2004;24(4):379-385.
25. Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry. 2006;67(4):554-566. (Pubitemid 43764232)
26. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci. 2000;20(22):8620-8628.
27. Carroll JK, Kohli S, Mustian KM, et al. Pharmacologic treatment of cancer-related fatigue. Oncologist. 2007;12(suppl 1):43-51.
28. Rammohan KW, Rosenberg JH, Lynn DJ, et al. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry. 2002;72(2):179-183.
29. Rabkin JG, Gordon PH, McElhiney M, et al. Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study. Muscle Nerve. 2009;39(3):297-303.
30. Ondo WG, Fayle R, Atassi F, et al. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005;76(12):1636-1639.
31. Rabkin JG, McElhiney MC, Rabkin R, et al. Modafinil treatment for fatigue in HIV+ patients: a pilot study. J Clin Psychiatry. 2004;65(12):1688-1695.
32. Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry. 2000;61(5):378-381.
33. Lundt L. Modafinil improves winter depression in a pilot study. (abstract) Chronobiol Int. 2003;20(6):1217-1218.
34. DeBattista C, Doghramji K, Menza MA, et al; Modafinil in Depression Study Group. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64(9):1057-1064.
35. Price CS, Taylor FB. A retrospective chart review of the effects of modafinil on depression as monotherapy and as adjunctive therapy. Depress Anxiety. 2005;21(4):149-153.
36. Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007;164(8):1242-1249.
37. Ware JE Jr, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-483.
38. McElhiney M, Rabkin J, Van Gorp W. Modafinil effects on cognitive function in HIV+ patients treated for fatigue: a placebo controlled study [published online ahead of print November 24, 2009]. J Clin Exper Neuropsychol.
39. First MB, Gibbon M, Spitzer R, et al. User Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders. Washington, DC: American Psychiatric Association, 1996.
40. Guy W. Clinical Global Impressions (CGI) Scale. In: Rush A, First M, Blacker D, eds. Handbook of Psychiatric Measures. 2nd ed. Washington, DC: American Psychiatric Publishing; 2008:90-92.
41. Krupp LB, LaRocca NG, Muir-Nash J, et al. The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121-1123.
42. Whitehead L. The measurement of fatigue in chronic illness: a systematic review of unidimensional and multidimensional fatigue measures. J Pain Symptom Manage. 2009;37(1):107-128.
43. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-545.
44. Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. J Psychosom Res. 1993;37(2):147-153.
45. Williams JBW. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;45(8):742-747.
46. Beck AT, Steer RA, Brown GK. Beck Depression Inventory-II Manual. San Antonio, TX: Psychological Corp; 1996.
47. Rabkin JG, Markowitz JS, Ocepek-Welikson K, et al. General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. J Clin Psychopharmacol. 1992;12(1):3-10.
48. Maj M, D'Elia L, Satz P, et al; World Health Organization, Division of Mental Health/Global Programme on AIDS. Evaluation of two new neuropsychological tests designed to minimize cultural bias in the assessment of HIV-1 seropositive persons: a WHO study. Arch Clin Neuropsychol. 1993;8(2):123-135.
49. Wechsler D. Wechsler Adult Intelligence Scale-Third Edition (WAIS-III). San Antonio, TX: Psychological Corp; 1997.
50. D'Elia L, Satz P, Uchiyama C, et al. Color Trails Test. Odessa, FL: Psychological Assessment Resources, Inc.; 1996.
51. Golden CJ. Stroop Word and Color Test: A Manual for Clinical and Experimental Uses. Chicago, IL: Stoetling Co; 1978.
52. Matthews C, Klove H. Instruction Manual for the Adult Neuropsychology Test Battery. Madison, WI: University of Wisconsin Medical School; 1964.
53. Benton AL, Lezak M, Howieson D, et al, eds. Neuropsychological Assessment. 4th ed. New York, NY: Oxford University Press; 2004:519-520.
54. Miller EN. California Computerized Assessment Battery (CalCAP) Manual. Los Angeles, CA: Norland Software; 1990.
55. AIDS Education and Training Centers National Resource Center. 2009. http://www.aidsetc.org/
56. Centers for Disease Control and Health Prevention. MMWR Recommendations and Reports. 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm. Published December 18, 1992. Accessed March 11, 2010.
57. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789-1799.
58. Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008;33(7):1477-1502.
59. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997;126(9):712-720.
60. Moscucci M, Byrne L, Weintraub M, et al. Blinding, unblinding, and the placebo effect: an analysis of patients' guesses of treatment assignment in a double-blind clinical trial. Clin Pharmacol Ther. 1987;41(3):259-265.